Publication Topic

Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genet Toxicol Environ Mutagen 800-801(April):28-34; doi: 10.1016/j.mrgentox.2016.01.008.

Becker RA, Patlewicz G, Simon T, Rowlands JC, Budinsky RA. 2015. The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor. Regul Toxicol Pharmacol 73(1):172-190; doi: 10.1016/j.yrtph.2015.06.015. PMID: 26145830.

Patlewicz G, Simon T, Rowlands JC, Budinsky R, Becker RA. 2015. Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes. Regul Toxicol Pharmacol 71(3):463-477; doi: 10.1016/j.yrtph.2015.02.011. PMID: 25707856. (Top 10 Paper for RASS Award at SOT 2016)

 Suh M, Thompson CM, Harris MA. 2013. Mode of action evaluation for hexavalent chromium-induced lung cancer. Presented at Society of Toxicology 52nd Annual Meeting, March 10-14, San Antonio, TX.